Through the acquisition, BD (Becton, Dickinson and Company) gains the scientific leadership and insights of Ger van den Engh, a renowned innovator in flow cytometry. Dr van den Engh will join BD Biosciences, a segment of BD, as vice president, Advanced Cytometry. In this role, he will manage continuing research and technology development activities in Seattle.
William Kozy, BD’s executive vice president, said: “This strategic acquisition brings new technologies and capabilities that will enhance BD’s ability to address growing customer needs in advanced applications, such as cell therapy research. This transaction reflects our commitment to bringing innovative tools to life scientists and will allow us to rapidly enter emerging areas of cell-based research.”